BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Radiology 2019;292:25-34. [PMID: 31012818 DOI: 10.1148/radiol.2019182326] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev 2020;88:102030. [PMID: 32505807 DOI: 10.1016/j.ctrv.2020.102030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
2 Geboers B, Timmer FEF, Ruarus AH, Pouw JEE, Schouten EAC, Bakker J, Puijk RS, Nieuwenhuizen S, Dijkstra M, van den Tol MP, de Vries JJJ, Oprea-Lager DE, Menke-van der Houven van Oordt CW, van der Vliet HJ, Wilmink JW, Scheffer HJ, de Gruijl TD, Meijerink MR, On Behalf Of The Dutch Pancreatic Cancer Group. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. Cancers (Basel) 2021;13:3902. [PMID: 34359801 DOI: 10.3390/cancers13153902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liao H, Ahmed M, Markezana A, Zeng G, Stechele M, Galun E, Goldberg SN. Thermal Ablation Induces Transitory Metastatic Growth by Means of the STAT3/c-Met Molecular Pathway in an Intrahepatic Colorectal Cancer Mouse Model. Radiology 2020;294:464-72. [PMID: 31845846 DOI: 10.1148/radiol.2019191023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Lyu N, Kong Y, Li X, Mu L, Deng H, Chen H, He M, Lai J, Li J, Tang H, Lin Y, Zhao M. Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Front Oncol 2020;10:580241. [PMID: 33163408 DOI: 10.3389/fonc.2020.580241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yu B, Zhang W, Kwak K, Choi H, Kim DH. Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy. ACS Appl Mater Interfaces 2020;12:54415-25. [PMID: 33237729 DOI: 10.1021/acsami.0c15679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dalili D, Isaac A, Bazzocchi A, Åström G, Bergh J, Lalam R, Weber MA, Fritz J, Mansour R. Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part I. Ablation. Semin Musculoskelet Radiol 2020;24:692-709. [PMID: 33307585 DOI: 10.1055/s-0040-1719103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol 2020;21:e419-30. [PMID: 32888471 DOI: 10.1016/S1470-2045(20)30234-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 26.0] [Reference Citation Analysis]
8 Murali N, Ludwig JM, Nezami N, Kim HS. Oligometastatic Disease and Interventional Oncology: Rationale and Research Directions. Cancer J 2020;26:166-73. [PMID: 32205542 DOI: 10.1097/PPO.0000000000000442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Adnan A, Muñoz NM, Prakash P, Habibollahi P, Cressman ENK, Sheth RA. Hyperthermia and Tumor Immunity. Cancers (Basel) 2021;13:2507. [PMID: 34063752 DOI: 10.3390/cancers13112507] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Veltri A, Calandri M. Thermal ablation and systemic therapies in the metastatic liver: time for a "glocal" approach. Eur Radiol 2019;29:5042-4. [PMID: 31209619 DOI: 10.1007/s00330-019-06290-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Helmberger T. The evolution of interventional oncology in the 21st century. Br J Radiol 2020;93:20200112. [PMID: 32706978 DOI: 10.1259/bjr.20200112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Leppelmann KS, Mooradian MJ, Ganguli S, Uppot RN, Yamada K, Irani Z, Wehrenberg-Klee EP, Zubiri L, Reynolds KL, Arellano RS, Hirsch JA, Sullivan RJ, Fintelmann FJ. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol 2021;32:187-95. [PMID: 33353814 DOI: 10.1016/j.jvir.2020.09.014] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim D, Erinjeri JP. Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology. Semin Intervent Radiol. 2019;36:334-342. [PMID: 31680725 DOI: 10.1055/s-0039-1696704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]